Dechert Advises AlgoTherapeutix in its €12 Million Series A Fundraising
Dechert advised AlgoTherapeutix, a French biotech company which develops topical pain relief treatment for chemotherapy-induced peripheral neuropathy (CIPN), in its €12 million Series A fundraising.
This financing round was co-led by Bpifrance, through its InnoBio 2 fund, and by Omnes, and also involved other existing and new private investors. The funds will allow AlgoTherapeutix to take ATX01 into clinical development in chemotherapy-induced peripheral neuropathy.
The Dechert team advising AlgoTherapeutix included corporate partner Anne-Charlotte Rivière and corporate associate Louis Taslé d’Héliand.
About Dechert
Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
